Cargando…
Two-Year Outcome of Aflibercept Intravitreal Injection in Vitrectomized Eyes with Diabetic Macular Edema
PURPOSE: To evaluate the efficacy of intravitreal aflibercept injection (IAI) for vitrectomized eyes with diabetic macular edema (DME) at two years. METHODS: This is a prospective, non-comparative, multicenter observational study including diabetic patients with visual acuity between 20/400 to 20/40...
Autores principales: | Tran, Thi Ha Chau, Verdun, Stephane, Le Rouic, Jean François, Uzzan, Joel, Milazzo, Solange, Kodjikian, Laurent, Erginay, Ali |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8923833/ https://www.ncbi.nlm.nih.gov/pubmed/35310546 http://dx.doi.org/10.2147/OPTH.S352152 |
Ejemplares similares
-
One-Year Outcome of Aflibercept Intravitreal Injection in Vitrectomized Eyes with Diabetic Macular Edema
por: Tran, Thi Ha Chau, et al.
Publicado: (2021) -
Choroidal Blood Flow After Intravitreal Ranibizumab in Vitrectomized and Non-Vitrectomized Eyes with Diabetic Macular Edema
por: Pessoa, Bernardete, et al.
Publicado: (2021) -
Intravitreal Tissue Plasminogen Activator Injection for Treatment-Resistant Diabetic Macular Edema of the Vitrectomized Eye
por: Aoki, Ren, et al.
Publicado: (2021) -
Evaluation of the Effect of Intravitreal Dexamethasone (Ozurdex(®)) Implant on Intraocular Pressure in Vitrectomized and Non-Vitrectomized Eyes with Macular Edema
por: Garlı, Murat, et al.
Publicado: (2021) -
Effectiveness of Intravitreal Dexamethasone Implant Treatment for Diabetic Macular Edema in Vitrectomized Eyes
por: Özdemir, Hüseyin Baran, et al.
Publicado: (2019)